Rezolute
Specializing in the development of drug therapies for patients with metabolic and orphan diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | $90.0m | Post IPO Equity |
| Total Funding | 000k | ||
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | - | - | - | - | (285 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Equity research estimates
Related Content
A late-stage biopharmaceutical company that specializes in developing therapies for rare diseases. The company's primary focus is on conditions with significant unmet medical needs, particularly congenital hyperinsulinism (HI), a rare pediatric genetic disorder characterized by excessive insulin secretion, leading to persistent hypoglycemia.
The company's lead product candidate, RZ358, is a human monoclonal antibody that is in late-stage clinical development for the treatment of congenital HI. RZ358 is designed to bind to and inhibit the activity of insulin, thereby reducing the frequency and severity of hypoglycemic events. Rezolute is also developing RZ402, an oral plasma kallikrein inhibitor for the treatment of diabetic macular edema (DME).
The company's business model is centered on the development and commercialization of its product candidates. Rezolute's target market includes pediatric and adult patients with rare diseases, as well as the physicians and healthcare providers who treat them. The company's revenue model will be based on the sale of its approved products.
Keywords: biopharmaceutical, rare diseases, congenital hyperinsulinism, hypoglycemia, monoclonal antibody, clinical development, orphan drugs, pediatric, genetic disorders, diabetic macular edema.